Ann: Investor Update, page-2

Very encouraging speech from the new Chairman:


There is a growing acknowledgment that immunotherapies will play a key role in the future treatment of cancer. The industry is investing heavily in this space, with combination treatments that may have synergistic mechanisms of action garnering the most attention.

There are currently over 1,100 active oncology combination trials. As the global leader in LAG-3, Immutep has an enormous opportunity to capitalise on this movement.

I am very confident that we have the right product candidates, industry collaborations and team of professionals to build a highly successful global biotechnology company. I am extremely focused on ensuring we are able to advance our unique combination trials, build on our clinical partnerships, deliver sensible commercial pathways, and enhance shareholder value.

As our focus is now on LAG-3, which already has a close association with the name Immutep, the name change will assist in providing greater visibility for our Company both in the industry and global investment markets. Our CEO, Marc Voigt, and the team have worked tirelessly to build our Company’s reputation and pipeline. I would like to thank all of the Immutep employees for their continued efforts.